Estrace vs. Bijuve
See how Estrace and Bijuve compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Estrace is an estrogen-only tablet that can be paired with a separate progestogen, while Bijuve combines estradiol and progesterone in one daily capsule for women with a uterus.
Estrace offers several tablet strengths and dosing schedules, while Bijuve comes in just two fixed-dose capsule strengths taken once a day.
Estrace has been available since 1975 and typically costs far less out of pocket than Bijuve, a newer combination product approved in 2018.
Estrace vs. Bijuve Drug Summary
Estrace
Estrace is an oral estrogen (estradiol) tablet approved for hot flashes, vaginal atrophy, hypoestrogenism, and prevention of postmenopausal osteoporosis. It is usually taken once daily at doses between 0.5 mg and 2 mg, with higher three-times-daily doses used for other approved conditions.
Bijuve
Bijuve is a combination oral capsule containing bioidentical estradiol and progesterone, approved for moderate to severe hot flashes in menopausal women who still have a uterus. It is taken once daily as a single fixed-dose capsule, available in two strengths.
Estrace vs. Bijuve Side Effects
Estrace
Bijuve
Estrace vs. Bijuve Dosage
Estrace
Bijuve
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg three times daily | At the start |
| Maximum dose | 10 mg three times daily | Same as starting |
| Dose changes | None | Fixed dose |
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg/100 mg once daily | At the start |
| Maximum dose | 1 mg/100 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Estrace
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg three times daily | At the start |
| Maximum dose | 10 mg three times daily | Same as starting |
| Dose changes | None | Fixed dose |
Bijuve
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg/100 mg once daily | At the start |
| Maximum dose | 1 mg/100 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Estrace vs. Bijuve Indications
Estrace
Estrace is FDA-approved for a broad set of estrogen-related conditions, from hot flashes and vaginal atrophy to low estrogen after ovarian failure. It is also approved for preventing osteoporosis and for palliative treatment of certain hormone-sensitive cancers.
Moderate to severe hot flashes of menopause
Vaginal dryness and vulvar/vaginal atrophy
Low estrogen from ovarian failure, hypogonadism, or castration
Prevention of osteoporosis after menopause
Bijuve
Bijuve has a single FDA-approved use: treating moderate to severe hot flashes in menopausal women who still have a uterus. It is not approved for vaginal atrophy, osteoporosis prevention, or use in women without a uterus.
Moderate to severe vasomotor symptoms (hot flashes) of menopause
For women who have a uterus and need progestogen protection
Not approved for women without a uterus
Not approved for vaginal atrophy or osteoporosis prevention
Estrace vs. Bijuve Pros and Cons
Estrace
Estrace is an estrogen-only tablet with decades of clinical use and several dosing options, but it requires an added progestogen for women with a uterus to protect against endometrial cancer. It generally costs far less than newer combination products, though coverage still varies by insurance plan.
Pros
Available in multiple tablet strengths for flexible dosing
FDA-approved for a wider range of conditions, including osteoporosis prevention and certain cancers
Long track record of use dating back to 1975
Cons
Estrogen-only formula requires a separate progestogen for women with a uterus
Higher-dose regimens require dosing three times a day
2 mg tablet contains tartrazine dye, which can trigger allergic reactions in some people
Bijuve
Bijuve packages bioidentical estradiol and progesterone into one capsule, simplifying treatment for women with a uterus who need both hormones. Its narrower approval and much higher price reflect its more recent entry into the market.
Pros
Combines estrogen and progesterone in a single daily capsule, no separate progestogen needed
Simple one-capsule-a-day dosing with only two strength options
Uses bioidentical micronized progesterone alongside bioidentical estradiol
Cons
Only approved for women who have a uterus
Approved for hot flashes only, not vaginal atrophy or osteoporosis prevention
Roughly $257 to $351 per month, substantially more than Estrace
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.